NeuBase Therapeutics, Inc.
Company Snapshot: NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc., a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
- Oct 17 2019 NeuBase Therapeutics Announces Issuance of Foundational Patent Covering the Key Building Blocks of PATrOL™ Enabled Therapies
- Oct 11 2019 NeuBase Therapeutics Announces Appointment of Cancer Biologist and RNA Therapeutics Specialist Steven Dowdy, Ph.D., to Scientific Advisory Board
- Sep 26 2019 NeuBase Therapeutics to Present at the Chardan 3rd Annual Genetic Medicines Conference
- Sep 9 2019 NeuBase Therapeutics Hosting Key Opinion Leader Meeting on Huntington's Disease and PATrOL™-Enabled Therapy on September 16th